PET/MRI scan for certain breast cancer types
Part of Cancer, Skin clinical trials.
This trial is studying if a special PET/MRI scan using a tracer called 18F FES can help doctors decide the best treatment for people with Luminal A or hormone-receptor-positive lobular breast cancer. The scan looks at estrogen receptors to see if your cancer might respond to hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with breast cancer that has not spread far (primary or locally advanced) and is either Luminal A or a type called lobular that is ER-positive.
- You are scheduled to have surgery as your first treatment, regardless of whether cancer is in your lymph nodes.
- Your cancer is ER-positive and HER2-negative, and has a Ki-67 score greater than 10%.
- You are not pregnant and do not have any condition that would prevent you from having a PET or MRI scan, such as claustrophobia, severe kidney problems, or an allergy to MRI contrast dye.
- Your tumor is not ER-negative (does not lack estrogen receptors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This trial uses a special imaging scan called 18F-FES PET/CT to help doctors plan treatment and check how well it works for breast cancer that is ER-positive (meaning the cancer cells grow in response to estrogen). It may help improve treatment choices and monitoring.
This trial uses a special PET scan called 4FMFES-PET to take detailed pictures of ER-positive breast cancer that has spread. It helps doctors see where the cancer is and how active it is, which may guide treatment decisions.
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.